{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:52:51Z","timestamp":1787698371828,"version":"build-2784847793"},"publisher-location":"New York, NY","reference-count":51,"publisher":"Springer New York","isbn-type":[{"value":"9781493973736","type":"print"},{"value":"9781493973743","type":"electronic"}],"license":[{"start":{"date-parts":[[2017,10,25]],"date-time":"2017-10-25T00:00:00Z","timestamp":1508889600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1007\/978-1-4939-7374-3_1","type":"book-chapter","created":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T11:08:50Z","timestamp":1508843330000},"page":"3-17","source":"Crossref","is-referenced-by-count":34,"title":["An Overview of Recent Therapeutics Advances for Duchenne Muscular Dystrophy"],"prefix":"10.1007","author":[{"given":"Jean K.","family":"Mah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,25]]},"reference":[{"key":"1_CR1","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1136\/jmg.30.6.506","volume":"30","author":"AE Emery","year":"1993","unstructured":"Emery AE, Emery ML (1993) Edward Meryon (1809-1880) and muscular dystrophy. J Med Genet 30:506\u2013511","journal-title":"J Med Genet"},{"key":"1_CR2","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","volume":"51","author":"EP Hoffman","year":"1987","unstructured":"Hoffman EP, Brown RH, Kunkel LM (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51:919\u2013928","journal-title":"Cell"},{"key":"1_CR3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0960-8966(91)90039-U","volume":"1","author":"AE Emery","year":"1991","unstructured":"Emery AE (1991) Population frequencies of inherited neuromuscular diseases \u2013 a world survey. Neuromuscul Disord 1:19\u201329","journal-title":"Neuromuscul Disord"},{"key":"1_CR4","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.nmd.2014.03.008","volume":"24","author":"JK Mah","year":"2014","unstructured":"Mah JK, Korngut L, Dykeman J, Day L, Pringsheim T, Jette N (2014) A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscul Disord 24:482\u2013491","journal-title":"Neuromuscul Disord"},{"key":"1_CR5","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/0888-7543(88)90113-9","volume":"2","author":"AP Monaco","year":"1988","unstructured":"Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM (1988) An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2:90\u201395","journal-title":"Genomics"},{"key":"1_CR6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/mus.20586","volume":"34","author":"A Aartsma-Rus","year":"2006","unstructured":"Aartsma-Rus A, Van Deutekom JC, Fokkema IF, Van Ommen GJ, Den Dunnen JT (2006) Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 34:135\u2013144","journal-title":"Muscle Nerve"},{"key":"1_CR7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby K, Finkel R, Birnkrant DJ et al (2010) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9:77\u201393","journal-title":"Lancet Neurol"},{"key":"1_CR8","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1017\/S0317167100011896","volume":"38","author":"JK Mah","year":"2011","unstructured":"Mah JK, Selby K, Campbell C et al (2011) A population-based study of dystrophin mutations in Canada. Can J Neurol Sci 38:465\u2013474","journal-title":"Can J Neurol Sci"},{"key":"1_CR9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/mus.23807","volume":"48","author":"CM McDonald","year":"2013","unstructured":"McDonald CM, Henricson EK, Abresch RT et al (2013) The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used. Muscle Nerve 48:32\u201354","journal-title":"Muscle Nerve"},{"key":"1_CR10","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.4155\/cli.11.113","volume":"1","author":"K Bushby","year":"2011","unstructured":"Bushby K, Connor E (2011) Clinical outcome measures for trials in Duchenne muscular dystrophy: report from international working group meetings. Clin Investig (Lond) 1:1217\u20131235","journal-title":"Clin Investig (Lond)"},{"key":"1_CR11","doi-asserted-by":"publisher","unstructured":"Henricson E, Abresch R, Han JJ et al (2013) The 6-minute walk test and person-reported outcomes in boys with Duchenne muscular dystrophy and typically developing controls: longitudinal comparisons and clinically-meaningful changes over one year. PLoS Curr 5. doi: 10.1371\/currents.md.9e17658b007eb79fcd6f723089f79e06","DOI":"10.1371\/currents.md.9e17658b007eb79fcd6f723089f79e06"},{"key":"1_CR12","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.nmd.2009.06.368","volume":"19","author":"ES Mazzone","year":"2009","unstructured":"Mazzone ES, Messina S, Vasco G et al (2009) Reliability of the north star ambulatory assessment in a multicentric setting. Neuromuscul Disord 19:458\u2013461","journal-title":"Neuromuscul Disord"},{"key":"1_CR13","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1212\/WNL.0b013e318227b164","volume":"77","author":"DM Escolar","year":"2011","unstructured":"Escolar DM, Hache LP, Clemens PR et al (2011) Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology 77:444\u2013452","journal-title":"Neurology"},{"key":"1_CR14","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/mus.21808","volume":"42","author":"CM McDonald","year":"2010","unstructured":"McDonald CM, Henricson EK, Han JJ et al (2010) The 6-minute walk test in Duchenne\/Becker muscular dystrophy: longitudinal observations. Muscle Nerve 42:966\u2013974","journal-title":"Muscle Nerve"},{"key":"1_CR15","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/mus.23905","volume":"48","author":"CM McDonald","year":"2013","unstructured":"McDonald CM, Henricson EK, Abresch RT et al (2013) The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve 48:357\u2013368","journal-title":"Muscle Nerve"},{"key":"1_CR16","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/mus.23902","volume":"48","author":"CM McDonald","year":"2013","unstructured":"McDonald CM, Henricson EK, Abresch RT et al (2013) The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve 48:343\u2013356","journal-title":"Muscle Nerve"},{"key":"1_CR17","volume":"9","author":"M Pane","year":"2014","unstructured":"Pane M, Mazzone ES, Sivo S et al (2014) Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes. PLoS One 9:e108205","journal-title":"PLoS One"},{"key":"1_CR18","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/WNL.0b013e318225ab2e","volume":"77","author":"E Mazzone","year":"2011","unstructured":"Mazzone E, Vasco G, Sormani MP et al (2011) Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. Neurology 77:250\u2013256","journal-title":"Neurology"},{"key":"1_CR19","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/cbe611fe-cda9-4d98-9574-0ac18e109daa","volume":"8","author":"ES Mazzone","year":"2013","unstructured":"Mazzone ES, Pane M, Sormani MP et al (2013) 24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy. PLoS One 8:e52512","journal-title":"PLoS One"},{"key":"1_CR20","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/pri.221","volume":"6","author":"B Steffensen","year":"2001","unstructured":"Steffensen B, Hyde S, Lyager S, Mattsson E (2001) Validity of the EK scale: a functional assessment of non-ambulatory individuals with Duchenne muscular dystrophy or spinal muscular atrophy. Physiother Res Int 6:119\u2013134","journal-title":"Physiother Res Int"},{"key":"1_CR21","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.nmd.2012.06.006","volume":"22","author":"E Mercuri","year":"2012","unstructured":"Mercuri E, McDonald C, Mayhew A et al (2012) International workshop on assessment of upper limb function in Duchenne muscular dystrophy: Rome, 15-16 February 2012. Neuromuscul Disord 22:1025\u20131028","journal-title":"Neuromuscul Disord"},{"key":"1_CR22","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/dmcn.12213","volume":"55","author":"A Mayhew","year":"2013","unstructured":"Mayhew A, Mazzone ES, Eagle M et al (2013) Development of the performance of the upper limb module for Duchenne muscular dystrophy. Dev Med Child Neurol 55:1038\u20131045","journal-title":"Dev Med Child Neurol"},{"key":"1_CR23","doi-asserted-by":"publisher","unstructured":"Pane M, Mazzone ES, Sivo S et al (2014) The 6 minute walk test and performance of upper limb in ambulant duchenne muscular dystrophy boys. PLoS Curr 6. doi: 10.1371\/currents.md.a93d9904d57dcb08936f2ea89bca6fe6","DOI":"10.1371\/currents.md.a93d9904d57dcb08936f2ea89bca6fe6"},{"key":"1_CR24","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.nmd.2010.03.007","volume":"20","author":"V Arechavala-Gomeza","year":"2010","unstructured":"Arechavala-Gomeza V, Kinali M, Feng L et al (2010) Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: implication for clinical trials. Neuromuscul Disord 20:295\u2013301","journal-title":"Neuromuscul Disord"},{"key":"1_CR25","doi-asserted-by":"crossref","first-page":"7153","DOI":"10.1073\/pnas.1507719112","volume":"112","author":"Y Hathout","year":"2015","unstructured":"Hathout Y, Brody E, Clemens PR et al (2015) Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 112:7153\u20137158","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1_CR26","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/ana.24599","volume":"79","author":"RJ Willcocks","year":"2016","unstructured":"Willcocks RJ, Rooney WD, Triplett WT et al (2016) Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort. Ann Neurol 79:535\u2013547","journal-title":"Ann Neurol"},{"key":"1_CR27","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","volume":"74","author":"JR Mendell","year":"2013","unstructured":"Mendell JR, Rodino-Klapac LR, Sahenk Z et al (2013) Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 74:637\u2013647","journal-title":"Ann Neurol"},{"key":"1_CR28","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.24555","volume":"79","author":"JR Mendell","year":"2016","unstructured":"Mendell JR, Goemans N, Lowes LP et al (2016) Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol 79:257\u2013271","journal-title":"Ann Neurol"},{"key":"1_CR29","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/jmedgenet-2015-103387","volume":"53","author":"A Aartsma-Rus","year":"2016","unstructured":"Aartsma-Rus A, Ginjaar IB, Bushby K (2016) The importance of genetic diagnosis for Duchenne muscular dystrophy. J Med Genet 53:145\u2013151","journal-title":"J Med Genet"},{"key":"1_CR30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081302","volume":"8","author":"RS Finkel","year":"2013","unstructured":"Finkel RS, Flanigan KM, Wong B et al (2013) Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy. PLoS One 8:e81302","journal-title":"PLoS One"},{"key":"1_CR31","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mus.24332","volume":"50","author":"K Bushby","year":"2014","unstructured":"Bushby K, Finkel R, Wong B et al (2014) Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve 50:477\u2013487","journal-title":"Muscle Nerve"},{"key":"1_CR32","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/mt.2013.246","volume":"22","author":"LG Chicoine","year":"2014","unstructured":"Chicoine LG, Rodino-Klapac LR, Shao G et al (2014) Vascular delivery of rAAVrh74.MCK.GALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin \u03b12 surrogates. Mol Ther 22:713\u2013724","journal-title":"Mol Ther"},{"key":"1_CR33","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3390\/ph6070813","volume":"6","author":"T Okada","year":"2013","unstructured":"Okada T, Takeda S (2013) Current challenges and future directions in recombinant AAV-mediated gene therapy of Duchenne muscular dystrophy. Pharmaceuticals (Basel) 6:813\u2013836","journal-title":"Pharmaceuticals (Basel)"},{"key":"1_CR34","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.1111\/febs.12273","volume":"280","author":"D Briggs","year":"2013","unstructured":"Briggs D, Morgan JE (2013) Recent progress in satellite cell\/myoblast engraftment \u2013 relevance for therapy. FEBS J 280:4281\u20134293","journal-title":"FEBS J"},{"key":"1_CR35","doi-asserted-by":"publisher","unstructured":"Ito M, Ehara Y, Li J, Inada K, Ohno K (2016) Protein-anchoring therapy of Biglycan for mdx mouse model of Duchenne muscular dystrophy. Hum Gene Ther. doi: 10.1089\/hum.2015.088","DOI":"10.1089\/hum.2015.088"},{"key":"1_CR36","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1093\/hmg\/ddv154","volume":"24","author":"S Guiraud","year":"2015","unstructured":"Guiraud S, Squire SE, Edwards B et al (2015) Second-generation compound for the modulation of utrophin in the therapy of DMD. Hum Mol Genet 24:4212\u20134224","journal-title":"Hum Mol Genet"},{"key":"1_CR37","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/ana.10385","volume":"52","author":"KR Wagner","year":"2002","unstructured":"Wagner KR, McPherron AC, Winik N, Lee SJ (2002) Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol 52:832\u2013836","journal-title":"Ann Neurol"},{"key":"1_CR38","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nature01154","volume":"420","author":"S Bogdanovich","year":"2002","unstructured":"Bogdanovich S, Krag TO, Barton ER et al (2002) Functional improvement of dystrophic muscle by myostatin blockade. Nature 420:418\u2013421","journal-title":"Nature"},{"key":"1_CR39","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jneuroim.2006.03.005","volume":"175","author":"F Andreetta","year":"2006","unstructured":"Andreetta F, Bernasconi P, Baggi F et al (2006) Immunomodulation of TGF-beta 1 in mdx mouse inhibits connective tissue proliferation in diaphragm but increases inflammatory response: implications for antifibrotic therapy. J Neuroimmunol 175:77\u201386","journal-title":"J Neuroimmunol"},{"key":"1_CR40","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2119\/molmed.2013.00011","volume":"19","author":"S Consalvi","year":"2013","unstructured":"Consalvi S, Mozzetta C, Bettica P et al (2013) Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat. Mol Med 19:79\u201387","journal-title":"Mol Med"},{"key":"1_CR41","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.nmd.2016.07.002","volume":"26","author":"P Bettica","year":"2016","unstructured":"Bettica P, Petrini S, D'Oria V et al (2016) Histological effects of givinostat in boys with Duchenne muscular dystrophy. Neuromuscul Disord 26:643\u2013649","journal-title":"Neuromuscul Disord"},{"key":"1_CR42","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.2147\/DDDT.S110163","volume":"10","author":"S Miyatake","year":"2016","unstructured":"Miyatake S, Shimizu-Motohashi Y, Takeda S, Aoki Y (2016) Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors. Drug Des Devel Ther 10:2745\u20132758","journal-title":"Drug Des Devel Ther"},{"key":"1_CR43","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1212\/WNL.0000000000001950","volume":"85","author":"L Bello","year":"2015","unstructured":"Bello L, Gordish-Dressman H, Morgenroth LP et al (2015) Prednisone\/prednisolone and deflazacort regimens in the CINRG Duchenne natural history study. Neurology 85:1048\u20131055","journal-title":"Neurology"},{"key":"1_CR44","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/emmm.201302621","volume":"5","author":"CR Heier","year":"2013","unstructured":"Heier CR, Damsker JM, Yu Q et al (2013) VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. EMBO Mol Med 5:1569\u20131585","journal-title":"EMBO Mol Med"},{"key":"1_CR45","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/j.2040-4603.2015.tb00638.x","volume":"5","author":"QQ Gao","year":"2015","unstructured":"Gao QQ, McNally EM (2015) The Dystrophin complex: structure, function, and implications for therapy. Compr Physiol 5:1223\u20131239","journal-title":"Compr Physiol"},{"key":"1_CR46","first-page":"420","volume":"6","author":"EO Hern\u00e1ndez-Ochoa","year":"2015","unstructured":"Hern\u00e1ndez-Ochoa EO, Pratt SJ, Lovering RM, Schneider MF (2015) Critical role of intracellular RyR1 calcium release channels in skeletal muscle function and disease. Front Physiol 6:420","journal-title":"Front Physiol"},{"key":"1_CR47","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.toxicon.2006.09.030","volume":"49","author":"CL Bowman","year":"2007","unstructured":"Bowman CL, Gottlieb PA, Suchyna TM, Murphy YK, Sachs F (2007) Mechanosensitive ion channels and the peptide inhibitor GsMTx-4: history, properties, mechanisms and pharmacology. Toxicon 49:249\u2013270","journal-title":"Toxicon"},{"key":"1_CR48","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1474-4422(09)70272-8","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby K, Finkel R, Birnkrant DJ et al (2010) Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 9:177\u2013189","journal-title":"Lancet Neurol"},{"key":"1_CR49","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1161\/CIRCULATIONAHA.114.015151","volume":"131","author":"EM McNally","year":"2015","unstructured":"McNally EM, Kaltman JR, Benson DW et al (2015) Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, lung, and blood institute in collaboration with Parent Project Muscular Dystrophy. Circulation 131:1590\u20131515","journal-title":"Circulation"},{"key":"1_CR50","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/ppul.21254","volume":"45","author":"DJ Birnkrant","year":"2010","unstructured":"Birnkrant DJ, Bushby KM, Amin RS et al (2010) The respiratory management of patients with Duchenne muscular dystrophy: a DMD care considerations working group specialty article. Pediatr Pulmonol 45:739\u2013748","journal-title":"Pediatr Pulmonol"},{"key":"1_CR51","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bonekey.2012.5","volume":"1","author":"VH Morgenroth","year":"2012","unstructured":"Morgenroth VH, Hache LP, Clemens PR (2012) Insights into bone health in Duchenne muscular dystrophy. Bonekey Rep 1:9","journal-title":"Bonekey Rep"}],"container-title":["Methods in Molecular Biology","Duchenne Muscular Dystrophy"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-7374-3_1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T18:20:05Z","timestamp":1750962005000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-7374-3_1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,25]]},"ISBN":["9781493973736","9781493973743"],"references-count":51,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-7374-3_1","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,25]]}}}